Moreover, HSP90 inhibitor 17-AAG could exert anti-inflammatory effects, and control the progression of diverse inflammatory diseases, such as autoimmune dermatitis (Tukaj et al., 2017), uveitis (Poulaki et al., 2007), etc. The current study demonstrated that 17-AAG dose-dependently restored NP inflammation and catabolism by simultaneously ameliorating the inflammatory phenotype of macrophages and NPCs. The gene discussed is HSP90AA1; the disease is uveitis.